S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
NCT00856492
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Monoclonal antibodies, such as... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/23/2017
Locations: Providence Cancer Center at Providence Hospital, Mobile, Alabama +365 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00280150
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by bloc... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/19/2017
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina +2 locations
Conditions: Lung Cancer
Register for Updates
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
NCT00662311
Terminated
This phase I/II trial studies the side effects and best dose of vorinostat when given together with paclitaxel and radiation therapy and to see how well it works in treating patients unable to tolerate cisplatin with stage III non-small cell lung cancer (NSCLC) that cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor ce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2017
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
NCT01778803
Completed
This is a Phase I/Ib, open-label, multicenter, dose-escalation trial of paclitaxel in combination with defactinib (VS-6063), a focal adhesion kinase inhibitor, in patients with advanced ovarian cancer. This clinical study is comprised of 2 parts: Phase I (Dose Escalation) and Phase Ib (Expansion). The purpose of this study is to assess assess the safety (including the recommended phase 2 dose), the pharmacokinetics, and the anti-cancer activity of defactinib (VS-6063) when administered in combin... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2017
Locations: Florida Cancer Specialists, Sarasota, Florida +2 locations
Conditions: Ovarian Cancer
Register for Updates
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00550537
Completed
RATIONALE: Studying samples of tumor tissue, blood, and urine in the laboratory from patients receiving erlotinib may help doctors predict how patients will respond to treatment. PURPOSE: The phase II trial is studying proteomic profiling to see how well it predicts response in patients receiving erlotinib for stage IIIB, stage IV, or recurrent non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/12/2017
Locations: University of Florida Shands Cancer Center, Gainesville, Florida +6 locations
Conditions: Lung Cancer
Register for Updates
Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer
NCT00503906
Completed
The investigators hypothesize that the combination of Gemzar®, Abraxane® and Avastin will increase the progression-free survival (PFS) in patients with first line metastatic breast cancer and in patients who received neoadjuvant and/or adjuvant chemotherapy present with definable metastatic disease, 6 or more months after primary treatment.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/10/2017
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer
Register for Updates
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
NCT01108055
Completed
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with relapsed recurrent urothelial cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2017
Locations: Stanford University School of Medicine, Stanford, California +1 locations
Conditions: Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Register for Updates
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
NCT01558492
Terminated
The purpose of this study is to look at the clinical benefit of carboplatin and paclitaxel and correlate response to study treatment with biologic parameters (i.e. lab studies of blood, urine, or tissue). It is hoped that this will allow researchers to gain insight into the underlying biology of prostate tumor progression and perhaps predict which patients may benefit from this chemotherapy regimen.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/05/2017
Locations: Weill Cornell Medical College, New York, New York
Conditions: Prostate Cancer
Register for Updates
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
NCT02338115
Completed
The purpose of this prospective observational study is to understand the relationship between paclitaxel exposure and development of peripheral neuropathy during treatment.
Gender:
FEMALE
Ages:
19 years and above
Trial Updated:
05/01/2017
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Breast Cancer
Register for Updates
Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer
NCT01227408
Withdrawn
The investigators propose to conduct a clinical trial of neoadjuvant treatment utilizing chemotherapy formulations with favorable toxicity profiles: weekly doxorubicin, PPX and capecitabine. It is expected this combination will at least maintain the efficacy of a traditional chemotherapy regimen but will be associated with less toxicity, particularly nausea, vomiting and alopecia. In order to accomplish this the investigators have designed a chemotherapy regimen whose components (or administrati... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/29/2017
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Breast Cancer
Register for Updates
Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
NCT00459810
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estradiol may kill prostate cancer cells that no longer respond to hormone therapy. Giving paclitaxel poliglumex together with estradiol may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel poliglumex together with estradiol works in treating patients with stage IV... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
04/26/2017
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +1 locations
Conditions: Prostate Cancer
Register for Updates
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
NCT00093119
Completed
This trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine. The new chemotherapy will be administered weekly in cycles of three weekly doses followed by one week rest. A minimum of three cycles of therapy will be given to determine the anti-tumor response of the new chemotherapy. Patients may continue to stay on therapy a maximum of 9-12 cycles if treatment shows continuing benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2017
Locations: Abraxis BioScience Inc., Durham, North Carolina
Conditions: Melanoma, Metastases
Register for Updates